Hutchmed China Ltd - Company Profile
Powered by
All the data and insights you need on Hutchmed China Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Hutchmed China Ltd Strategy Report
- Understand Hutchmed China Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Hutchmed China Ltd’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
10 Feb 2022 | Genetron Holdings Enters into Agreement with Hutchmed China | Partnership | - |
Hutchmed China Ltd
Genetron Holdings Limited
|
09 Aug 2021 | Epizyme Enters into Licensing Agreement with Hutchmed China | Licensing Agreement |
Hutchmed China Ltd
|
Epizyme Inc |
03 Aug 2021 | Hutchison MediPharma Ltd Enters Phase III Clinical Trial Agreement with Labcorp Drug Development for savolitinib (GDCT0415841) | Contract Service Agreement |
Hutchison MediPharma Ltd
|
Labcorp Drug Development
|
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer